Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Colorectal cancer (CRC) remains one of the most common cancers worldwide. Increasing evidence indicates that SPRY4 intronic transcript 1 (SPRY4-IT1) regulate cell growth, differentiation, apoptosis, and cancer progression. However, the expression and function of SPRY4-IT1 in the progression of CRC remains largely unknown. Here, we reported that SPRY4-IT1 was upregulated in CRC. Increased SPRY4-IT1 expression in CRC was associated with larger tumor size and higher clinical stage. In vitro experiments revealed that SPRY4-IT1 knockdown significantly inhibited CRC cell proliferation by causing G1 arrest and promoting apoptosis, whereas SPRY4-IT1 overexpression promoted cell proliferation. Further functional assays indicated that SPRY4-IT1 overexpression significantly promoted cell migration and invasion by regulate the epithelial-mesenchymal transition (EMT). Taken together, our study demonstrates that SPRY4-IT1 could act as a functional oncogene in CRC, as well as a potential therapeutic target to inhibit CRC metastasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362419 | PMC |
| http://dx.doi.org/10.18632/oncotarget.10407 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dissecting the role of SPRY4-IT1 and TUG1 in modulating miR-425/TGF-β/ Smad signaling in mediating renal fibrosis and inflammation in lupus nephritis: Novel biomarkers and therapeutic targets.
Int Immunopharmacol
September 2025
Collage of Pharmacy, University of Kut, Wasit, 52001, Iraq; Department of Biochemistry, Faculty of Pharmacy, Egyptian Russian University, Cairo 11829, Egypt.
Lupus nephritis (LN), the severe complication of systemic lupus erythematosus (SLE), is driven by inflammation and fibrosis, often leading to chronic kidney diseases. The current study aimed to elucidate the roles of long non-coding RNAs (lncRNAs) SPRY4-IT1 and TUG1, and miR-425 in modulating the TGF-β/Smad signaling pathway and to assess their potential as biomarkers and therapeutic targets. A case-control study was conducted involving 100 participants, including LN patients (n = 35), SLE patients without LN (n = 35), and healthy controls (n = 30).
View Article and Find Full Text PDF: A Crucial Competing Endogenous RNA in Cancer Research-A Scoping Review.
Adv Biomed Res
May 2025
Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Recently, research on the competing endogenous RNAs (ceRNAs) in cancer has been in full swing, emphasizing their importance as critical RNAs in cancer progression. Enhancer of zeste 2 polycomb repressive complex 2 subunit () is a ceRNA that has been introduced as a potential therapeutic target in many cancers. Due to EZH2's dual role as an oncogene and tumor suppressor in cancer, a more thorough exploration of its ceRNA functions may enhance clinical cancer treatment approaches.
View Article and Find Full Text PDFResearch progress on function and mechanism of long non-coding RNA in glioma.
Cell Mol Biol (Noisy-le-grand)
May 2024
The First Hospital of Shanxi Medical University, Taiyuan, China.
This review aimed to comprehensively summarize the role of long non-coding RNA (lncRNA) in gliomas, the most common malignant tumors in the central nervous system, and explore their potential clinical applications. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search using the PubMed database was conducted forty studies met the inclusion and exclusion criteria and were analyzed for type of intervention, the study's design, participants' demographics, and outcomes, including attrition. Gliomas, originating within the central nervous system, account for 40-45% of intracranial tumors.
View Article and Find Full Text PDF